Ikena Oncology Inc
North American company
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
Latest IKNA News